PMID-40713699 — Chen: Metformin + Semaglutide in PCOS (RCT, Reprod Biol Endocrinol 2025)

[DRAFT — authored 2026-04-20. Citation verified against PubMed 2026-04-20.]

Citation

Chen H, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025;23(1):108. doi: 10.1186/s12958-025-01447-3. PMID: 40713699.

External URL: PubMed

Study Design

Design: Prospective, randomized, controlled, open-label clinical trial
N: 100 women with PCOS (80% completed)
Population: Overweight or obese women with polycystic ovary syndrome
Arms: Metformin + semaglutide (COM) vs metformin alone (MET)
Duration: 16 weeks (primary outcomes) + 16-40 week reproductive-outcome follow-up

Key Findings

Weight and metabolic outcomes at 16 weeks

Combination (COM) group: 6.09 ± 3.34 kg weight loss
Metformin alone (MET) group: 2.25 ± 4.27 kg weight loss
COM group also showed greater reductions in BMI, waist-to-hip ratio, testosterone, visceral adiposity index, and inflammatory markers

Reproductive outcomes

Enhanced menstrual cycle recovery in COM group
Natural pregnancy rate (weeks 16-40): 35% (COM) vs 15% (MET alone), P<0.05

Clinical Relevance

Chen 2025 is a small-RCT early signal that combining semaglutide with metformin in PCOS may produce additive benefits on weight, metabolic parameters, and reproductive outcomes beyond metformin monotherapy. Core teaching points:

Open-label design limits causal inference — blinding was not implemented; placebo effects and Hawthorne-type effects cannot be excluded.
Small sample (n=100; 80 completers) — adequate for weight-loss primary but underpowered for robust reproductive-outcome inference.
Pregnancy-outcome signal requires cautious framing — if clinicians pursue semaglutide in PCOS-associated infertility, patients must be counseled on the general recommendation to discontinue GLP-1 RAs upon pregnancy awareness (see PMID 40329607). Using semaglutide specifically to induce pregnancy while simultaneously recommending discontinuation upon pregnancy creates a clinical tension that must be navigated carefully.
Not an FDA-approved indication: PCOS is NOT an indicated population for semaglutide. Use is off-label and must be explicitly counseled.
Evidence tier: Phase 2-level, hypothesis-generating. Larger confirmatory trials (and preferably blinded designs) are needed before this evidence can support routine clinical use.

Linked Peptides

Semaglutide
Metformin (background standard-of-care comparator; not vault-linked but cited)

Related Lessons

Lesson 5.2 — Semaglutide Deep Dive (Emerging Indications)

Related Studies

PMID-40329607 – Parker GLP-1 Pregnancy Regulatory Safety Data — pregnancy-safety context for any PCOS-fertility indication discussion

PMID-40713699 – Chen Metformin Semaglutide PCOS RCT